William Blair Investment Management LLC Buys Shares of 258,173 ANI Pharmaceuticals, Inc. $ANIP

William Blair Investment Management LLC purchased a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the second quarter, Holdings Channel reports. The fund purchased 258,173 shares of the specialty pharmaceutical company’s stock, valued at approximately $21,372,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in ANIP. KBC Group NV bought a new position in ANI Pharmaceuticals in the 1st quarter valued at approximately $28,000. Advisors Asset Management Inc. acquired a new position in ANI Pharmaceuticals in the 1st quarter valued at approximately $28,000. Hantz Financial Services Inc. raised its stake in shares of ANI Pharmaceuticals by 70.3% during the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after acquiring an additional 249 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new position in shares of ANI Pharmaceuticals during the fourth quarter worth $48,000. Finally, State of Wyoming bought a new stake in shares of ANI Pharmaceuticals in the second quarter worth $50,000. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ:ANIP opened at $75.35 on Friday. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. The stock has a market cap of $1.73 billion, a PE ratio of 16.24 and a beta of 0.44. The stock’s fifty day simple moving average is $80.36 and its two-hundred day simple moving average is $78.88. ANI Pharmaceuticals, Inc. has a 1-year low of $70.15 and a 1-year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.04 by $0.17. The firm had revenue of $266.04 million during the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The business’s revenue was up 25.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, analysts forecast that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on the company. Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Wall Street Zen downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Guggenheim dropped their target price on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Weiss Ratings lowered ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Finally, Canaccord Genuity Group dropped their price objective on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research note on Monday, August 10th. Four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $105.83.

Insider Activity

In other ANI Pharmaceuticals news, Director Thomas Haughey sold 2,000 shares of the stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $80.88, for a total value of $161,760.00. Following the completion of the sale, the director owned 38,878 shares in the company, valued at approximately $3,144,452.64. This trade represents a 4.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen P. Carey sold 3,313 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $86.00, for a total transaction of $284,918.00. Following the transaction, the chief financial officer directly owned 177,543 shares in the company, valued at approximately $15,268,698. This represents a 1.83% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 18,987 shares of company stock valued at $1,546,405 in the last three months. 8.10% of the stock is owned by company insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.